Key Points
- Biotech stocks have a reputation for being high risk, high reward.
- Many of the stocks Wall Street thinks can double (or better) over the next 12 months are biotechs.
- Although Denali has yet to commercialize a product, analysts are encouraged by its progress and collaborations with major biopharmaceutical players.
- Since its May 4th report, seven analysts have reiterated buy ratings on Ultragenyx compared to one hold.
- 5 stocks we like better than Denali Therapeutics
Upgrade Now
This premium article is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.
Already have an account? Log in here.
Before you consider Denali Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Denali Therapeutics wasn't on the list.
While Denali Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
